A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

The current disclosure relates to a combination of ingredients including Plumeria alba (Frangipani) flower extract and salicylic acid. The composition can further contain hydroxyacetophenone, titanium dioxide, and/or carrageenan. This combination of components has been shown to be useful as a cleansing composition that is effective for reducing sebum, increasing clarity of the skin, and for improving the appearance of the skin by reducing shine and pore size. This combination of components has further been shown to be useful for reducing irritation and inflammation in the skin.

The current disclosure relates to a combination of ingredients including Plumeria alba (Frangipani) flower extract and salicylic acid. The composition can further contain hydroxyacetophenone, titanium dioxide, and/or carrageenan. This combination of components has been shown to be useful as a cleansing composition that is effective for reducing sebum, increasing clarity of the skin, and for improving the appearance of the skin by reducing shine and pore size. This combination of components has further been shown to be useful for reducing irritation and inflammation in the skin.

The current disclosure relates to a combination of ingredients including Plumeria alba (Frangipani) flower extract and salicylic acid. The composition can further contain hydroxyacetophenone, titanium dioxide, and/or carrageenan. This combination of components has been shown to be useful as a cleansing composition that is effective for reducing sebum, increasing clarity of the skin, and for improving the appearance of the skin by reducing shine and pore size. This combination of components has further been shown to be useful for reducing irritation and inflammation in the skin.

Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

The present invention relates to compositions and methods for potentiating glutathione enhancement for use in brain health. In particular, the compositions and methods of the invention are beneficial for use in subjects in need of increasing motivational performance and/or mental energy, functions that may be decreased upon stress and anxiety.

The present disclosure provides a dual-drag-containing nanoparticle, in which a first antiviral drag, such as remdesivir and a second antiviral drag are co-encapsulated and co-delivered by the nanoparticle, said nanoparticle comprising an alginate-oleic acid particle. The disclosure also relates to the therapeutic use of the nanoparticle in treating viral infections, such as SARS-CoV-2.

The present disclosure provides a dual-drag-containing nanoparticle, in which a first antiviral drag, such as remdesivir and a second antiviral drag are co-encapsulated and co-delivered by the nanoparticle, said nanoparticle comprising an alginate-oleic acid particle. The disclosure also relates to the therapeutic use of the nanoparticle in treating viral infections, such as SARS-CoV-2.

The present disclosure provides a dual-drag-containing nanoparticle, in which a first antiviral drag, such as remdesivir and a second antiviral drag are co-encapsulated and co-delivered by the nanoparticle, said nanoparticle comprising an alginate-oleic acid particle. The disclosure also relates to the therapeutic use of the nanoparticle in treating viral infections, such as SARS-CoV-2.